指南与共识血栓与止血

美国血液学会2021指南:癌症患者静脉血栓栓塞的预防与治疗

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.
指南 / 共识 · Blood Adv · 2021-01-01

美国血液学会(ASH)基于系统证据综述和GRADE方法制定循证指南,针对癌症患者静脉血栓栓塞(VTE)的预防与治疗提出推荐。指南涵盖住院、手术及门诊化疗患者的预防,以及VTE初始、短期和长期抗凝治疗,并区分强推荐与条件推荐。

要点

  • 低VTE风险的门诊化疗患者不推荐血栓预防(强推荐)。
  • 癌症患者VTE初始治疗推荐使用低分子肝素(强推荐)。
  • 住院内科癌症患者可考虑血栓预防(条件推荐)。

核心结论

  • 强推荐包括:低VTE风险的门诊化疗患者不使用血栓预防,以及癌症患者VTE初始治疗使用低分子肝素(LMWH)。
  • 条件推荐包括:住院内科癌症患者使用血栓预防,手术癌症患者使用LMWH或磺达肝癸钠。

研究设计与样本

  • ASH组建多学科指南小组,以最小化利益冲突偏倚,由更新或新的系统证据综述支持。
  • 采用GRADE方法评估证据并制定推荐。

主要发现

  • 推荐涉及住院内科癌症患者、接受手术的癌症患者及接受化疗的门诊患者的机械和药物预防。
  • 推荐涉及癌症患者VTE初始、短期和长期抗凝治疗的使用。

关键数值与推荐

  • 强推荐:低VTE风险的门诊化疗患者不使用血栓预防。
  • 强推荐:癌症患者VTE初始治疗使用LMWH。
  • 条件推荐:住院内科癌症患者使用血栓预防。
  • 条件推荐:手术癌症患者使用LMWH或磺达肝癸钠。
  • 条件推荐:高VTE风险接受全身治疗的门诊癌症患者使用LMWH或直接口服抗凝药(DOAC)。

临床怎么用

  • 根据患者所属人群(住院内科、手术、门诊化疗)及VTE风险选择预防策略。
  • 癌症患者VTE初始治疗优先选择LMWH(强推荐)。
  • 短期治疗可选用DOAC,长期治疗可选用LMWH或DOAC(条件推荐)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) is a common complication among patients with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and mortality. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of VTE in patients with cancer. METHODS: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The guideline development process was supported by updated or new systematic evidence reviews. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess evidence and make recommendations. RESULTS: Recommendations address mechanical and pharmacological prophylaxis in hospitalized medical patients with cancer, those undergoing a surgical procedure, and ambulatory patients receiving cancer chemotherapy. The recommendations also address the use of anticoagulation for the initial, short-term, and long-term treatment of VTE in patients with cancer. CONCLUSIONS: Strong recommendations include not using thromboprophylaxis in ambulatory patients receiving cancer chemotherapy at low risk of VTE and to use low-molecular-weight heparin (LMWH) for initial treatment of VTE in patients with cancer. Conditional recommendations include using thromboprophylaxis in hospitalized medical patients with cancer, LMWH or fondaparinux for surgical patients with cancer, LMWH or direct oral anticoagulants (DOAC) in ambulatory patients with cancer receiving systemic therapy at high risk of VTE and LMWH or DOAC for initial treatment of VTE, DOAC for the short-term treatment of VTE, and LMWH or DOAC for the long-term treatment of VTE in patients with cancer.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021. PMID: 33570602. doi:10.1182/bloodadvances.2020003442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。